“Treat-all”Strategy for Patients with Chronic Hepatitis B Virus Infection in China:Are We There Yet?  

作　　者：Mengyang Zhang Yuanyuan Kong Xiaoqian Xu Yameng Sun Jidong Jia Hong You 

机构地区：[1]Liver Research Center,Beijing Friendship Hospital,Capital Medical University,Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis,National Clinical Research Center of Digestive Diseases,State Key Lab of Digestive Health,Beijing,China [2]Clinical Epidemiology and EBM Unit,Beijing Friendship Hospital,Capital Medical University,Beijing Clinical Research Institute,Beijing,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第6期589-593,共5页临床与转化肝病杂志（英文版）

基　　金：supported by the National Key Research and Development Program(2023YFC2306900);the Beijing Municipal Science&Technology Commission(Z221100007422115).

摘　　要：Chronic hepatitis B remains the primary cause of liver-related events in China.The World Health Organization set a goal to eliminate viral hepatitis as a public health threat by 2030.However,achieving this goal appears challenging due to the current low rates of diagnosis and treatment.The“Treat-all”strategy,which proposes treating all patients with detectable hepatitis B virus(HBV)DNA or even all patients with positive HBsAg,has been suggested to simplify anti-HBV treatment.In 2022,the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases updated the guidelines for the prevention and treatment of chronic hepatitis B in China,expanding antiviral indications and simplifying the treatment algorithm.According to this latest guideline,nearly 95%of patients with detectable HBV DNA are eligible for antiviral treatment.This review aimed to provide a detailed interpretation of the treatment indications outlined in the Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis B(version 2022)and to identify gaps in achieving the“Treat-all”strategy in China.

关 键 词：Chronic hepatitis B Antiviral therapy Treatment indication Expanding treatment Treatment rate “Treat-all”strategy 

分 类 号：R512.62[医药卫生—内科学]